Genome Editing Technology Articles & Analysis
58 news found
CD Genomics, a leading provider of genomic services, is proud to announce a groundbreaking advancement in microsatellite development that is set to transform the landscape of genetic research. Leveraging the power of next-generation sequencing (NGS), CD Genomics enables researchers to harness the full potential of microsatellite markers for a wide range of applications. Microsatellites, also ...
As the field of genomics continues to evolve, long non-coding RNAs (lncRNAs) have emerged as a fascinating frontier, offering unprecedented insights into the complex regulatory mechanisms underlying biological processes and disease states. CD Genomics, a leading provider of high-throughput sequencing services, is at the forefront of this exciting development, empowering researchers to unlock the ...
CD Genomics, a trailblazer in genomics and epigenomics research, is proud to announce the launch of MeRIP Sequencing, a cutting-edge technology revolutionizing the analysis of m6A modifications on RNA molecules. This breakthrough method promises to provide researchers with unparalleled insights into the dynamic world of epigenetic modifications, setting a new standard in precision ...
CD Genomics, a prominent leader in the genomics and transcriptomics arena, proudly unveils its latest innovation, the Degradome Sequencing service. This technology promises to revolutionize the field of transcriptomics research, offering researchers an unprecedented window into RNA degradation patterns and elevating our comprehension of gene regulation and expression. RNA degradation is a ...
CD Genomics, an excellent leader in genomics and bioinformatics, has unveiled a groundbreaking leap forward in TCR-Seq technology, poised to revolutionize immune repertoire profiling. With an unwavering commitment to innovation and precision, CD Genomics continues to redefine the genomics research landscape. TCR-Seq, short for T Cell Receptor Sequencing, is an instrumental tool that enables ...
CD Genomics, a global leader in genomics solutions, has recently unveiled its highly anticipated DAP-Seq service. This cutting-edge offering promises to provide researchers worldwide with an efficient application solution for DNA affinity purification sequencing technology. With this service, the company aims to revolutionize the field of life sciences and empower researchers to unlock the ...
CD Genomics, a leading provider of genomic solutions, has announced a groundbreaking development in genomic research with the introduction of their Full-Length Transcripts Sequencing (Iso-Seq) technology. This innovative advancement promises to revolutionize the field, providing researchers in the life sciences with an unprecedented opportunity to gain comprehensive insights into the complexity ...
Roswell Biotechnologies, Inc., the molecular electronics company, announced today the formation of its Scientific Advisory Board (SAB). Comprised of industry and academic leaders in science and technology, the new SAB will be instrumental in the final stages of development and commercialization of the company's molecular electronics chip, a fully scalable universal biosensor capable of seeing ...
Tavros to receive $17.5M upfront, up to $430.5M in milestone payments for initial four programs, and certain royalties over agreement term / Vividion will have rights to opt-in to up to five more targets for up to $482M in additional payments /Partnership to define novel drug targets and biomarkers, in addition to positioning existing compounds Tavros Therapeutics, Inc., a precision oncology ...
ByBayer AG
Strategic tech leadership appointment comes as industries race to innovate as part of the Bio Revolution - driving demand for advanced, AI-augmented knowledge discovery capabilities Tarun’s impressive career of >25 years includes tech leadership positions in the financial and security sectors Eagle Genomics, the platform business pioneering the application of network science to ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that the Company has signed an agreement with Greenstone Biosciences Inc. in Palo Alto, CA for the development of a human induced ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Jefferies Healthcare Conference Date: Thursday, June 9 at 9:00 a.m. Eastern Time Guggenheim I&I Spotlight Series – Treg-based Therapies Date: Tuesday, July 12 at 2:45 p.m. Eastern Time Access links for presentations, ...
CD Genomics is a world-leading genomics services company, innovating in sequencing services for the genomics industry as well as genotyping, library construction, bioinformatics, aptamers, microarrays, health diagnostics, mutagenesis analysis, and more. CD Genomics launches fully-developed human mitochondrial DNA (mtDNA) sequencing for the study of mitochondrial genome-related diseases, such as ...
This strategy is enabled by our proprietary Cas12a chRDNA genome-editing technology that reproducibly achieves high specificity genome editing at multiple ...
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
The Bioinformatics-analysis division is a new division of CD Genomics that provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. CD Genomics recently launched various types of genotyping analysis services, including analysis of data generated by different ...
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients In the first two dose cohorts, all four patients exhibited above normal α-Gal A activity, ranging from 3-fold to 15-fold above mean normal; patients in the first dose cohort have maintained elevated activity for one year and are now in the long-term ...
Presentations will focus on the progression of Sangamo’s pre-clinical programs emerging from its genomic engineering platform. “The data to be presented at ASGCT reflect the diversity and versatility of Sangamo’s genomic engineering platform, which is being deployed across a range of pre-clinical programs,” said Jason Fontenot, Ph.D., ...
C2i Genomics, a cancer intelligence company, today announced expansion into Europe through a strategic partnership with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers ...
“We will vigorously investigate alternative options to bring this genomic medicine forward to patients.” Sanofi notified Sangamo of its termination for convenience on December 30, 2021. ...